CAS Number83919-23-7
SynonymsMometasone furoate; (11β,16α)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate; 9,21-Dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate); Rimelon; Danitin; Mometasone furoate (JAN/USP); Ecural; Mometasone Furoate; Nosorex; (11b,16a)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione; (11β,16α)-9,21-Dichlor-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-ylfuran-2-carboxylat; 9,21-Dichloro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione17-(2-Furoate); Flumeta; MFCD00866003; (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; (11b,16a)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
Molecular FormulaC27H30Cl2O6
Molecular Weight521.43
Purity98%
Density1.4±0.1 g/cm3
Boiling Point655.5±55.0 °C at 760 mmHg
Melting Point218-220°C
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 83919-23-7 |
| Catalog No. | 2A-9011486 |
| Chinese Name | 糠酸莫米松 |
| Synonyms | Mometasone furoate; (11β,16α)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate; 9,21-Dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate); Rimelon; Danitin; Mometasone furoate (JAN/USP); Ecural; Mometasone Furoate; Nosorex; (11b,16a)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione; (11β,16α)-9,21-Dichlor-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-ylfuran-2-carboxylat; 9,21-Dichloro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione17-(2-Furoate); Flumeta; MFCD00866003; (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; (11b,16a)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| Molecular Formula | C27H30Cl2O6 |
| Molecular Weight | 521.43 |
| Purity | 98 |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 655.5±55.0 °C at 760 mmHg |
| Melting Point | 218-220°C |
| Storage Condition | Store at -20°C |
| Application | Mometasone furoate is the original drug of free form mometasone and has a high affinity for glucocorticoid receptors. |
| HTC | 2937229000 |
| PubChem ID | 329823374 |
| MDL Number | MFCD00866003 |
| SMILES | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c5ccco5)C(=O)CCl |
| InChI | 1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1 |
| InChI Key | WOFMFGQZHJDGCX-ZULDAHANSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/11486_1_83919_23_7.pdf |
| Bioactivity | Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.IC50 value: Target: glucocorticosteroid receptorMometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma [1]. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma [2]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor Research Areas >> Inflammation/Immunology References [1]. Tan RA, et al. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. [2]. Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract. 2009 May;63(5):806-19. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 655.5±55.0 °C at 760 mmHg Melting Point 218-220°C Molecular Formula C27H30Cl2O6 Molecular Weight 521.43 Flash Point 350.2±31.5 °C PSA 113.02000 LogP 4.27 Vapour Pressure 0.0±2.1 mmHg at 25°C Index of Refraction 1.604 InChIKey WOFMFGQZHJDGCX-ZULDAHANSA-N SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl Storage condition Store at -20°C |
| Use of | Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.IC50 value: Target: glucocorticosteroid receptorMometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma [1]. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma [2]. Properties Articles60 Name mometasone furoate Synonym More Synonyms Mometasone furoate Biological Activity Description Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.IC50 value: Target: glucocorticosteroid receptorMometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma [1]. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma [2]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor Research Areas >> Inflammation/Immunology References [1]. Tan RA, et al. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. [2]. Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract. 2009 May;63(5):806-19. Chemical & Physical Properties PSA 113.02000 Index of Refraction 1.604 InChIKey WOFMFGQZHJDGCX-ZULDAHANSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Midazolam | 59467-64-0 | 2A-9011438 |
| Miglitol | 72432-03-2 | 2A-9011445 |
| Minocycline hydrochloride | 13614-98-7 | 2A-9011457 |
| Mirtazapine | 85650-52-8 | 2A-9011463 |
| Moexipril | 103775-10-6 | 2A-9011482 |
| Montelukast sodium | 151767-02-1 | 2A-9011498 |
| Morphine N-oxide | 639-46-3 | 2A-9011507 |
| Moxifloxacin hydrochloride | 186826-86-8 | 2A-9011514 |
| Mycophenolate Mofeil | 2A-302613 | 2A-9011530 |
| Mycophenolate mofetil | 128794-94-5 | 2A-9011531 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS